Johnson & Johnson Testing Experimental HIV Vaccine In U.S., Europe, Africa

CNBC: Johnson & Johnson to test HIV vaccine in U.S. and Europe
“Pharmaceutical giant Johnson & Johnson is set to test an experimental HIV vaccine in the U.S. and Europe sometime this year, the company confirmed with CNBC. The experimental J&J vaccine is a mosaic-based preventative immunization that targets various strains of the HIV virus. … The company is also conducting a phase 2 clinical trial for the vaccine in Africa, in which 2,600 women in five southern African countries will be immunized. Initial results from that trial are expected by 2021, J&J said…” (Lovelace/Turner, 7/12).

Additional coverage of the upcoming clinical trial is available from Bloomberg and Reuters.

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.